These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation. Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351 [TBL] [Abstract][Full Text] [Related]
4. The novel isoflavone derivatives inhibit RANKL-induced osteoclast formation. Tang CH; Chang CS; Tan TW; Liu SC; Liu JF Eur J Pharmacol; 2010 Dec; 648(1-3):59-66. PubMed ID: 20850430 [TBL] [Abstract][Full Text] [Related]
5. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal. Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731 [TBL] [Abstract][Full Text] [Related]
6. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways. Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253 [TBL] [Abstract][Full Text] [Related]
7. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways. Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972 [TBL] [Abstract][Full Text] [Related]
8. Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways. Hu JP; Nishishita K; Sakai E; Yoshida H; Kato Y; Tsukuba T; Okamoto K Eur J Pharmacol; 2008 Feb; 580(1-2):70-9. PubMed ID: 18083161 [TBL] [Abstract][Full Text] [Related]
9. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. Valverde P; Tu Q; Chen J J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638 [TBL] [Abstract][Full Text] [Related]
10. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of osteoclast differentiation and bone resorption by sauchinone. Han KY; Yang D; Chang EJ; Lee Y; Huang H; Sung SH; Lee ZH; Kim YC; Kim HH Biochem Pharmacol; 2007 Sep; 74(6):911-23. PubMed ID: 17662251 [TBL] [Abstract][Full Text] [Related]
13. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells. Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913 [TBL] [Abstract][Full Text] [Related]
14. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha. Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109 [TBL] [Abstract][Full Text] [Related]
15. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling. Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790 [TBL] [Abstract][Full Text] [Related]
16. The natural flavonoid galangin inhibits osteoclastic bone destruction and osteoclastogenesis by suppressing NF-κB in collagen-induced arthritis and bone marrow-derived macrophages. Huh JE; Jung IT; Choi J; Baek YH; Lee JD; Park DS; Choi DY Eur J Pharmacol; 2013 Jan; 698(1-3):57-66. PubMed ID: 22985747 [TBL] [Abstract][Full Text] [Related]
17. Estradiol protects against ethanol-induced bone loss by inhibiting up-regulation of receptor activator of nuclear factor-kappaB ligand in osteoblasts. Chen JR; Haley RL; Hidestrand M; Shankar K; Liu X; Lumpkin CK; Simpson PM; Badger TM; Ronis MJ J Pharmacol Exp Ther; 2006 Dec; 319(3):1182-90. PubMed ID: 16971503 [TBL] [Abstract][Full Text] [Related]
18. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production. Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985 [TBL] [Abstract][Full Text] [Related]
19. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts. Ikeda F; Matsubara T; Tsurukai T; Hata K; Nishimura R; Yoneda T J Bone Miner Res; 2008 Jun; 23(6):907-14. PubMed ID: 18251700 [TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption. Park CK; Kim HJ; Kwak HB; Lee TH; Bang MH; Kim CM; Lee Y; Chung DK; Baek NI; Kim J; Lee ZH; Kim HH Int Immunopharmacol; 2007 Dec; 7(12):1507-16. PubMed ID: 17920527 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]